

# Melvin T Chin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7168035/publications.pdf>

Version: 2024-02-01

22  
papers

318  
citations

1040056

9  
h-index

839539

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

706  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | What does co-design mean for Australia's diverse clinical workforce?. Australian Health Review, 2022, 46, 60-61.   | 1.1 | 4         |
| 2  | Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma. Internal Medicine Journal, 2022, 52, 1103-1104.                    | 0.8 | 0         |
| 3  | Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. Public Health Research and Practice, 2021, 31, .                               | 1.5 | 5         |
| 4  | Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.  | 3.0 | 1         |
| 5  | Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: the CanEngage Project protocol. BMJ Open, 2021, 11, e048389.                            | 1.9 | 8         |
| 6  | Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial. BMC Cancer, 2020, 20, 342.       | 2.6 | 1         |
| 7  | Patient, general practitioner and oncologist views regarding long-term cancer shared care. Family Practice, 2018, 35, 323-329.   | 1.9 | 34        |
| 8  | Using behaviour change and implementation science to address low referral rates in oncology. BMC Health Services Research, 2018, 18, 904.  | 2.2 | 22        |
| 9  | The plot thickens: Archetypal narrative structure in the melanoma patient journey. Cogent Medicine, 2018, 5, 1484053.  | 0.7 | 1         |
| 10 | Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy. Kidney and Blood Pressure Research, 2017, 42, 62-75.                               | 2.0 | 18        |
| 11 | Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Research Notes, 2016, 9, 386.               | 1.4 | 6         |
| 12 | The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. Oncologist, 2016, 21, 618-625.  | 3.7 | 12        |
| 13 | Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: a study protocol. BMC Health Services Research, 2016, 16, 89. | 2.2 | 9         |
| 14 | Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. Oncology and Therapy, 2016, 4, 103-116.   | 2.6 | 5         |
| 15 | Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. Melanoma Research, 2014, 24, 408-412.   | 1.2 | 7         |
| 16 | Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2014, 20, 4449-4458.   | 7.0 | 56        |
| 17 | Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. BMC Research Notes, 2014, 7, 505.   | 1.4 | 11        |
| 18 | Use of neostigmine in capecitabine-induced paralytic ileus. Tumori, 2013, 99, e225-e228.   | 1.1 | 1         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Use of neostigmine in capecitabine-induced paralytic ileus. <i>Tumori</i> , 2013, 99, e225-8.   | 1.1  | 1         |
| 20 | Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 597-605. | 2.3  | 64        |
| 21 | Rationale for treatment durations of targeted cancer agents. <i>Lancet Oncology, The</i> , 2010, 11, 1113-1115.   | 10.7 | 3         |
| 22 | Primary pancreatic lymphoma “ pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. <i>BMC Cancer</i> , 2006, 6, 117.          | 2.6  | 49        |